Prostate Cancer Foundation

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2023 CHALLENGE AWARDS TOTALING MORE THAN $21 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Thursday, March 14, 2024
University of Illinois Urbana-Champaign, PCF, University of Sydney, Prostate cancer, Genetic testing, Immunotherapy, Prostate Cancer Foundation, Lund University, Oncogene, Patient, PET, Biomarker, Research, Aircraft pilot, University, Doctor of Philosophy, Biology, MBA, MPH, Johns Hopkins University, Institute of Cancer Research, CBP, University of Pretoria, PSMA, Medical imaging

LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 20 highly coveted PCF Challenge Awards totaling $21.3 million were granted to teams at some of the world's leading cancer research institutions.
  • (Evaluating the impact of treatment with darolutamide on age-related outcomes in vulnerable, older patients with metastatic hormone-sensitive prostate cancer.)

2024 JUSTICE RUTH BADER GINSBURG LEADERSHIP AWARD HONORS ELON MUSK, SYLVESTER STALLONE, MARTHA STEWART, MICHAEL MILKEN, AND RUPERT MURDOCH

Retrieved on: 
Wednesday, March 13, 2024
Ruth Bader Ginsburg, Champ, Democracy, Congress, Veteran, Prostate Cancer Foundation, Portrait, HM, RBG, Prostate cancer, Rocky, Woman, Bangladesh Technical Education Board, Supreme court, Justice, Parity, Thomas Jefferson Building, Sole proprietorship, Multimedia, Musk, Parent

RBG Leadership Award expands to honor Elon Musk, Sylvester Stallone, Martha Stewart, Michael Milken & Rupert Murdock

Key Points: 
  • RBG Leadership Award expands to honor Elon Musk, Sylvester Stallone, Martha Stewart, Michael Milken & Rupert Murdock
    Established in 2020, the RBG Award has previously recognized women of distinction, including HM Queen Elizabeth II and Barbra Streisand.
  • "Justice Ginsburg fought not only for women but for everyone," said Julie Opperman, Chair of the Dwight D. Opperman Foundation.
  • "Justice Ginsburg became an icon by bravely pursuing her own path and prevailing against the odds," said Brendan V. Sullivan, Jr., chair of the RBG Award.
  • Murdoch said: "I am deeply honored to receive the Justice Ruth Bader Ginsburg Leadership Award from the Dwight D. Opperman Foundation.

THE PROSTATE CANCER FOUNDATION AND THE AMERICAN CANCER SOCIETY ANNOUNCE FIRST ACS-PCF YOUNG INVESTIGATOR AWARD

Retrieved on: 
Thursday, February 22, 2024
Prostate Cancer Foundation, University College London, American Cancer Society, Doctor of Philosophy, Prostate cancer, PCF, PARP, ACS, Hospital, Geography, Mentorship, Organization, Patient, Health equity, Cone Health Women's Hospital, Research, Cancer, Partnership

LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.

Key Points: 
  • LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.
  • One in eight men in the U.S. will be diagnosed with prostate cancer in his lifetime, and it is the most commonly diagnosed non-skin cancer in men1.
  • "The Prostate Cancer Foundation has been funding research to understand and address prostate cancer disparities for more than 30 years," said Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, PCF.
  • "We are thrilled to have Dr. Cole as our ACS-PCF Young Investigator," said William Dahut, MD, Chief Scientific Officer, American Cancer Society.

Plant-Based Diet Tied to Improved Sexual Health in Men Treated for Prostate Cancer

Retrieved on: 
Tuesday, February 13, 2024
Master of Science, Bangladesh Technical Education Board, Nut, Prostate Cancer Foundation, Obstruction, Diabetes, Population health, Diet, National Institutes of Health, Prostate cancer, Dentist, Quality of life, Public health, Plant, Urinary incontinence, Harvard University, Hope, Veterinarian, Dietary fiber, SCM, Hot, Erectile dysfunction, Radiation, Meat, Risk, Pharmacist, University, NYU, Vegetable, History, Incontinence, Doctor of Science, White, Patient, MPH, Eating, Depression, Disease, NYU Langone Health, Male, Optometry, Research, Irritation, Dietary supplement

Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.

Key Points: 
  • Chan School of Public Health, the analysis of more than 3,500 men with prostate cancer explored whether eating a more plant-based diet was associated with quality-of-life issues that often arise after treatment.
  • Similarly, the results revealed up to 14% better scores for urinary health, with fewer instances of incontinence, obstruction, and irritation.
  • Prostate cancer is among the most common and deadliest forms of cancer among American men, according to the U.S. Centers for Disease Control and Prevention.
  • Funding for the study was provided by National Institutes of Health grant U01CA167552, New York State Department of Health, Tricia and Michael Berns, and the Prostate Cancer Foundation.

NEW PROSTATE CANCER FOUNDATION-FUNDED RESEARCH TO SPEED UP PROSTATE CANCER CLINICAL TRIALS WORLDWIDE

Retrieved on: 
Thursday, January 11, 2024
Prostate Cancer Foundation, UCL, University College London, Prostate cancer, Patient, Progression-free survival, Research, Prostate Cancer UK, Rated R, Survival, Metastasis, Duke University, Division, Food, Journal, Disease, Doctor of Philosophy, PMID, Clinical trial, Pharmaceutical industry

LOS ANGELES, Jan. 11, 2024 /PRNewswire/ -- New analysis of data published by Susan Halabi, PhD, of Duke University could facilitate approval of new prostate cancer treatments almost two years earlier than the current standard.

Key Points: 
  • The study published online January 5, 2024, in the Journal of Clinical Oncology , reviewed data from over 8,500 men in nine different clinical trials.
  • Dr. Halabi said, "Prostate cancer readout in men with metastatic prostate cancer can take a decade if survival is used as the main outcome.
  • This result highlights the importance of performing this analysis and maximizing the use of data from globally collected clinical trials.
  • Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.

EMBR LABS ANNOUNCES PUBLICATION OF GROUNDBREAKING STUDY ON HOT FLASHES IN PROSTATE CANCER PATIENTS IN PRESTIGIOUS NATURE JOURNAL

Retrieved on: 
Thursday, December 21, 2023
Quality of life, Prostate cancer, Prostate, Research, Dana–Farber Cancer Institute, Disease, Prostate Cancer Foundation, MD, Hot, Estate (law), Temperature, Death

BOSTON, Dec. 21, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading temperature wearable, today announced the publication of "Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer" in Nature Journal's Prostate Cancer and Prostatic Diseases.

Key Points: 
  • BOSTON, Dec. 21, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading temperature wearable, today announced the publication of "Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer" in Nature Journal's Prostate Cancer and Prostatic Diseases.
  • A first of its kind study, Embr labs collaborated with the Dana-Farber Cancer Institute in groundbreaking research in which men with prostate cancer found the Embr Wave device effective at managing hot flashes brought on by cancer treatment.
  • This is the first study to evaluate the feasibility of a wearable thermal device for nonmedicinal management of impactful hot flashes in prostate cancer patients.
  • "This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer."

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Breast, Acute respiratory distress syndrome, Safety, Telephone, Complaint, Mortality, Patient, Fast track (FDA), Infection, FDA, Prostate cancer, Prostate Cancer Foundation, Jeanne Eagels, Aerospace, COVID-19, Standard of care, Trial of the century, Death, P.C, Form 10-Q, Fast Track, News, Cryptocurrency, Pharmaceutical industry, Tiberius Claudius Verus

Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • At the time, there was no authorized or approved treatment for hospitalized patients with severe COVID-19 infections.

KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation

Retrieved on: 
Thursday, November 30, 2023
Finance, Medical Devices, Health, Professional Services, Health Technology, Breast, Investment, KKR, Prostate Cancer Foundation, Lung cancer, HOLX, Partnership, Growth, Biopsy, Medical imaging, Hologic

KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.

Key Points: 
  • KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.
  • The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke Rohlen.
  • Maverix will develop and acquire innovative technologies and commercial operations within the lung cancer disease category.
  • Each year, more people die of lung cancer than of colon, breast and prostate cancers combined.1
    KKR and Ajax Health will contribute existing portfolio company Serpex Medical to the platform.

THE PROSTATE CANCER FOUNDATION AND BAYER ANNOUNCE FIRST EVER BAYER-PCF HEALTH EQUITY RESEARCH CHALLENGE AWARDS

Retrieved on: 
Tuesday, December 5, 2023
Henry Ford Health, Health equity, Research, Risk assessment, Principal investigator, Patient, Prostate cancer, Master of Science, PCF, Prostate Cancer Foundation, University, Prostate saturation biopsy, Diagnosis, Cancer, Survival, Doctor of Philosophy, Michigan State University, Pharmaceutical industry, Medical imaging, Management, Black, Bayer, MD

LOS ANGELES, Dec. 5, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced three 2023 Bayer-PCF Health Equity Research Challenge Awards totaling $600,000.

Key Points: 
  • LOS ANGELES, Dec. 5, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced three 2023 Bayer-PCF Health Equity Research Challenge Awards totaling $600,000.
  • The awards will support novel health equity research projects with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer.
  • "The Prostate Cancer Foundation has been funding research to understand and address this disparity for more than 30 years," said Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, PCF.
  • "We are honored to partner with Bayer in this endeavor and congratulate the investigators on their research which we believe has the potential to reduce disparities in prostate cancer."

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
Radiation, FDA, Food, Therapy, Prostate Cancer Foundation, Flagship Pioneering, Head, Monroe Dunaway Anderson, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Restart, Partnership, Immunotherapy, University, Squamous-cell carcinoma, MD Anderson Cancer Center, Alpha, Cancer, Patient, Glioblastoma, Alpha Sigma Tau, Neck, Coronavirus Scientific Advisory Board, Pharmaceutical industry

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.

Key Points: 
  • JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.
  • “I am pleased to welcome Dr. Hahn to the Alpha Tau Scientific Advisory Board at an ideal time in the Company’s growth trajectory,” said Company CEO Uzi Sofer.
  • He previously served as FDA Commissioner from 2019 to 2021, overseeing regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
  • “I have been watching Alpha Tau’s development with excitement for quite some time,” said Dr. Hahn.